Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.05, MarketWatch Earnings reports. Rockwell Medical had a negative net margin of 55.38% and a negative return on equity of 89.63%. The business had revenue of $16.67 million during the quarter, compared to the consensus estimate of $15.00 million.

Shares of NASDAQ:RMTI traded up $0.79 during trading on Friday, hitting $4.38. 485,859 shares of the company were exchanged, compared to its average volume of 151,407. The company has a market capitalization of $198.54 million, a PE ratio of -8.59 and a beta of 1.42. Rockwell Medical has a 1-year low of $3.55 and a 1-year high of $6.98.

Large investors have recently made changes to their positions in the company. Sigma Investment Counselors Inc. increased its holdings in shares of Rockwell Medical by 24.3% during the third quarter. Sigma Investment Counselors Inc. now owns 86,834 shares of the company’s stock worth $366,000 after buying an additional 17,000 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Rockwell Medical by 13.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 108,942 shares of the company’s stock worth $538,000 after buying an additional 13,042 shares in the last quarter. Raymond James & Associates increased its holdings in shares of Rockwell Medical by 59.0% during the second quarter. Raymond James & Associates now owns 128,276 shares of the company’s stock worth $632,000 after buying an additional 47,600 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Rockwell Medical by 0.8% during the third quarter. BlackRock Inc. now owns 3,221,245 shares of the company’s stock worth $13,593,000 after buying an additional 25,322 shares in the last quarter. Institutional investors own 22.15% of the company’s stock.

RMTI has been the subject of several research analyst reports. ValuEngine upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, September 4th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, September 4th. Finally, Ifs Securities reiterated an “outperform” rating and set a $11.00 price target on shares of Rockwell Medical in a report on Friday, October 19th.

COPYRIGHT VIOLATION NOTICE: “Rockwell Medical (RMTI) Issues Quarterly Earnings Results” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/11/10/rockwell-medical-rmti-issues-quarterly-earnings-results.html.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.

Further Reading: Trading Strategy

Earnings History for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.